Cargando…
Overcoming Challenges to Make Bacteriophage Therapy Standard Clinical Treatment Practice for Cystic Fibrosis
Individuals with cystic fibrosis (CF) are given antimicrobials as prophylaxis against bacterial lung infection, which contributes to the growing emergence of multidrug resistant (MDR) pathogens isolated. Pathogens such as Pseudomonas aeruginosa that are commonly isolated from individuals with CF are...
Autores principales: | Ng, Renee N., Tai, Anna S., Chang, Barbara J., Stick, Stephen M., Kicic, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829477/ https://www.ncbi.nlm.nih.gov/pubmed/33505366 http://dx.doi.org/10.3389/fmicb.2020.593988 |
Ejemplares similares
-
Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?
por: Ling, Kak-Ming, et al.
Publicado: (2023) -
Complete Genomes of Three Pseudomonas aeruginosa Bacteriophages, Kara-mokiny 1, Kara-mokiny 2, and Kara-mokiny 3
por: Ng, Renee N., et al.
Publicado: (2022) -
Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis
por: Trend, Stephanie, et al.
Publicado: (2018) -
Pseudomonas aeruginosa Resistance to Bacteriophages and Its Prevention by Strategic Therapeutic Cocktail Formulation
por: Vaitekenas, Andrew, et al.
Publicado: (2021) -
A metagenomic approach to characterize temperate bacteriophage populations from Cystic Fibrosis and non-Cystic Fibrosis bronchiectasis patients
por: Tariq, Mohammad A., et al.
Publicado: (2015)